The Full Wiki

More info on Fosaprepitant

Fosaprepitant: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
[3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
CAS number 172673-20-0 265121-04-8 (dimeglumine)
ATC code A04AD12
PubChem 219090
Chemical data
Formula C 23H22F7N4O6P 
Mol. mass 614.406 g/mol
Pharmacokinetic data
Bioavailability n/a
Protein binding >95% (aprepitant)
Metabolism To aprepitant
Half life 9 to 13 hours (aprepitant)
Excretion  ?
Therapeutic considerations
Licence data

EU EMEA:linkUS FDA:link

Pregnancy cat. B(US)
Legal status -only (US)
Routes Intravenous

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008.[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2]

See also


Got something to say? Make a comment.
Your name
Your email address